History and Milestones

2010

• January: Agreement signed with Roche to create compounds with activity on targets in oncology and anti-infectives

2009

• January: Agreement signed with Summit for imino sugar compound
• January: Divinocell project commences
• March: Evolva starts Phase I Clinical Trials on EV-077
• July: Single Ascending Dose Trials on EV-077 successfully completed
• December: Evolva and Arpida merge to Evolva Holding SA

2008

• May: Army Research Office (ARO) contract awarded
• May: CRADA signed with U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
• November: Evolva receives award of funding from the Global Cardiovascular Innovation Center, Cleveland
• December: Submission of CTA for first-in-man study with new cardiovascular drug

2007

• January: Evolva led consortium (“Cappella”) awarded funding to conduct research on protein-protein interactions for cancer
• June: Evolva raises an additional CHF 12 mn from its existing investors.
• June: Evolva US (“Genetic Chemistry Inc”) incorporated

2006

• November: Contract signed with the U. S. Defense Threat Reduction Agency (DTRA) to discover therapeutics that improve the ability of humans to resist infections
• December: Collaboration signed with Functional Genetics to discover therapeutics against haemorrhagic fever viruses

2005

• April: Evolva India formed
• August: Evolva acquires certain assets of Poalis A/S, which form the basis of our current operations in Denmark

2004

• June: Evolva SA incorporated in Switzerland.
• August: Evolva raised c. CHF 21.8mn equity financing in it’s A-round